Becton Dickinson is combining its Biosciences & Diagnostic Solutions Business with Waters Corporation in a transaction valuing the BD unit at $4.1 billion and creating a combined entity with $6 billion in annual revenue. BD shareholders receive 78% of the new company, Waters shareholders 22%, with BD collecting $1 billion in cash at close and retaining a 20% tax-free stake in the separated diagnostics platform.

The deal isolates BD's highest-volume, lowest-margin diagnostics assets—specimen management, microbiology, and molecular diagnostics serving clinical laboratories—and pairs them with Waters' analytical instruments and chromatography systems used in pharmaceutical quality control and environmental testing. The combined business will serve regulated end-markets where instrument replacements and consumable streams are predictable but capital intensity is high. Waters CEO Udit Batra will lead the new entity, headquartered in Milford, Massachusetts, with expected close in the second half of 2025 pending customary regulatory clearance.

The structure reflects BD's decade-long pivot toward higher-margin medical technology, particularly smart connected devices and insulin delivery systems, where software layers and data integration command better multiples. BD's remaining med-tech segments—interventional, diabetes care, and medication management—generate 68% gross margins against the 55% typical in high-volume diagnostics. For Waters, the transaction more than doubles revenue scale and diversifies beyond its $2.5 billion base in analytical chemistry, where growth has stalled below 3% annually as pharmaceutical R&D budgets tighten. The diagnostics side brings installed base visibility: BD's specimen collection devices alone touch 30 million patient interactions daily across 10,000 hospital laboratories.

The separation carries execution risk. BD is carving out integrated IT systems, shared manufacturing footprint in Asia, and approximately 8,000 employees from a 77,000-person organization, with transaction costs likely exceeding $300 million based on comparable carve-outs in the med-tech sector. Waters assumes $2.5 billion in new debt to fund the cash component, pushing net leverage above 4x EBITDA at close—a steep load for a business historically run at 1.5x. The pro forma company will need to deliver $200 million in synergies by year three, primarily from procurement scale in reagents and lab consumables, to justify the leverage math.

Allocators should track three events through the second half of 2025. First, BD's investor day in late Q2, where management will detail capital allocation plans for the $1 billion cash proceeds and outline margin expansion targets for the remaining med-tech portfolio, likely including accelerated share buybacks. Second, the Waters-BD integration team's quarterly disclosures on manufacturing footprint decisions, particularly whether the combined entity keeps BD's Singapore biologics facility or consolidates into Waters' existing Massachusetts and UK plants. Third, regulatory filings in the EU and China, where antitrust review timelines will determine whether close slips into early 2026 and whether divestitures are required in overlapping chromatography product lines.

The $1 billion cash distribution to BD closes in a quarter where the company holds $3.2 billion in offshore cash and faces $1.8 billion in debt maturities through fiscal 2026.